NCT04930315 (CAPT) is a Phase 2 clinical trial of Apatinib Mesylate in Hepatocellular Carcinoma, sponsored by Zhejiang University.

Who is sponsoring NCT04930315?

NCT04930315 is sponsored by Zhejiang University.

What drugs are being tested in NCT04930315?

Interventions in NCT04930315: Apatinib Mesylate, Camrelizumab.

What condition does NCT04930315 study?

NCT04930315 studies Hepatocellular Carcinoma.

Is NCT04930315 still recruiting?

NCT04930315 is currently status unknown. Last updated 13 June 2023.

Last reviewed 2023-06-13 · How we verify

NCT04930315: CAPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma

Status unknown Phase 2 Last updated 13 June 2023

What this trial tests

Phase 2 trial testing Apatinib Mesylate in Hepatocellular Carcinoma in 78 participants. Status unknown.

Timeline

15 September 2021

Primary endpoint
30 June 2024

30 June 2024

Quick facts

Lead sponsor	Zhejiang University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	78
Start date	15 September 2021
Primary completion	30 June 2024
Estimated completion	30 June 2024
Sites	1 location across China

Drugs / interventions tested

Apatinib Mesylate
Camrelizumab — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Zhejiang University

Who can join

Adults 18 to 75, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to compare the efficacy and safety of camrelizumab + apatinib mesylate neoadjuvant therapy combined with camrelizumab adjuvant therapy and camrelizumab adjuvant therapy alone in patients with technically resectable hepatocellular carcinoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Neoadjuvant Therapy for Hepatocellular Carcinoma.
Yin Z, Chen D, Liang S, Li X. · · 2022 · cited 22× · PMID 36068876 · DOI 10.2147/jhc.s357313
Neoadjuvant Immunotherapy for Hepatocellular Carcinoma.
Marron TU, Schwartz M, Corbett V, Merad M. · · 2022 · cited 19× · PMID 35794901 · DOI 10.2147/jhc.s340935
Systemic Neoadjuvant and Adjuvant Therapies in the Management of Hepatocellular Carcinoma-A Narrative Review.
Chamseddine S, LaPelusa M, Kaseb AO. · · 2023 · cited 17× · PMID 37444618 · DOI 10.3390/cancers15133508
Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma.
Ao H, Xin Z, Jian Z. · · 2021 · cited 17× · PMID 34930486 · DOI 10.1186/s40364-021-00348-y
Neoadjuvant systemic therapy for hepatocellular carcinoma.
Chick RC, Ruff SM, Pawlik TM. · · 2024 · cited 16× · PMID 38495884 · DOI 10.3389/fimmu.2024.1355812
Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art.
Laschtowitz A, Roderburg C, Tacke F, Mohr R. · · 2023 · cited 13× · PMID 36789252 · DOI 10.2147/jhc.s347944
Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Zhao M, Chen S, Li C, Du Y, et al · · 2023 · cited 11× · PMID 36765557 · DOI 10.3390/cancers15030600
Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma.
Urquijo-Ponce JJ, Alventosa-Mateu C, Latorre-Sánchez M, Castelló-Miralles I, et al · · 2024 · cited 10× · PMID 38817666 · DOI 10.3748/wjg.v30.i19.2512

Verify or expand the search:

Other trials of Apatinib Mesylate

Trials testing the same drug.

NCT06539091 — Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer · Phase 3 · not yet recruiting
NCT06483282 — A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis i · Phase 2 · recruiting
NCT05751733 — Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST · NA · recruiting
NCT05613478 — Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma · Phase 3 · recruiting
NCT05524974 — Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant T · Phase 2 · not yet recruiting

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04930315 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 13 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04930315.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing